EyePoint Pharmaceuticals Files 8-K
Ticker: EYPT · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-update, financial-reporting
Related Tickers: EYPT
TL;DR
EYPT filed an 8-K on 12/04/24. Standard update.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on December 4, 2024, to report other events and financial statements. The company, formerly known as pSivida Corp., is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing indicates a routine update or event for EyePoint Pharmaceuticals, Inc., providing transparency to investors about the company's operational status and financial reporting.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 000-51122 — Commission File Number (Identifies the company's SEC filing history)
- 26-2774444 — IRS Employer Identification No. (Tax identification for the company)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- December 04, 2024 (date) — Date of earliest event reported
- 480 Pleasant Street, Watertown, Massachusetts 02472 (address) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' are being reported, but the specific details of these events are not provided in the header information.
What is the significance of the former company names 'pSivida Corp.' and 'pSivida LTD'?
These are former names of EyePoint Pharmaceuticals, Inc., indicating a history of corporate name changes.
What is the primary business of EyePoint Pharmaceuticals, Inc. based on its SIC code?
Based on the SIC code [3826], the company is involved in 'Laboratory Analytical Instruments'.
When was the company's most recent name change?
The company's name was changed from pSivida Corp. on June 19, 2008.
What is the fiscal year end for EyePoint Pharmaceuticals, Inc.?
The fiscal year end for EyePoint Pharmaceuticals, Inc. is December 31.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-12-04 07:05:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20241204.htm (8-K) — 40KB
- eypt-ex99_1.htm (EX-99.1) — 30KB
- img96707757_0.jpg (GRAPHIC) — 97KB
- 0000950170-24-133076.txt ( ) — 315KB
- eypt-20241204.xsd (EX-101.SCH) — 23KB
- eypt-20241204_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 4, 2024, EyePoint Pharmaceuticals, Inc. issued a press release announcing the first patient dosed in the Phase 3 LUCIA clinical trial of DURAVYU TM , formerly EYP-1901, for the treatment of wet age-related macular degeneration ("wet AMD"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc. dated December 4, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: December 4, 2024 By: /s/ George O. Elston George O. Elston Chief Financial Officer